Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

AstraZeneca Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (113)
Cancellation by sponsor (63)
Australian Public Assessment Report (AusPAR) (44)
Prescription medicine registration (42)
Designation or determination (21)
Prescription medicine evaluation (15)
Prescription medicine decision summary (11)
Section 14, TGO91 consent (1)

Date

2024 (37)
2023 (32)
2022 (45)
2021 (25)
2020 (16)
2019 (20)
2018 (19)
2017 (14)
2016 (11)
2015 (14)
2014 (13)
2013 (10)
2012 (3)
2011 (6)
2010 (4)
2008 (3)
2007 (1)
2006 (8)
2004 (2)
2003 (5)
2002 (3)
2001 (2)
1997 (2)
1996 (3)
1991 (12)

Results for "[search-keyword]"

Search

Sponsor content

310 result(s) found, displaying 251 to 260

PULMICORT TM RESPULES TM budesonide 0.25 mg in 2 mL spray suspension ampoule Cancelled under s30(1)(c )

14 July 2014

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
Pulmicort Respules budesonide 0.25mg/2mL inhalation ampoule Cancelled under s30(1)(c )

14 July 2014

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
Pulmicort Respules budesonide 0.5mg/2mL inhalation ampoule Cancelled under s30(1)(c )

14 July 2014

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
BETALOC CR metaprolol succinate 190mg Control Release tablet blister pack Cancelled under s30(1)(c)

9 July 2014

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
BETALOC CR metoprolol succinate 23.75mg tablet blister pack Cancelled under s30(1)(c)

9 July 2014

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
BETALOC CR metoprolol succinate 47.5mg Controlled Release tablet blister pack Cancelled under s30(1)(c)

9 July 2014

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
BETALOC CR Metoprolol succinate 95mg Control Release tablet blister pack Cancelled under s30(1)(c)

9 July 2014

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
AusPAR: Fentanyl (as citrate)

20 May 2014

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Fentanyl (as citrate)
AusPAR: Vandetanib

7 August 2013

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Vandetanib
AusPAR: Ceftaroline fosamil

22 May 2013

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Ceftaroline fosamil

Pages

First page
Previous page
…
Page 22
Page 23
Page 24
Page 25
Current page 26
Page 27
Page 28
Page 29
Page 30
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.